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Background: Human Papillomavirus (HPV) infection is known to be associated with a number of conditions including
cervical, vaginal, vulvar, penile, anal neoplasias and cancers, oropharynx cancers and genitals warts (GW). Two
prophylactic vaccines are currently available: a bivalent vaccine designed to prevent HPV type 16 and 18 infection and
a quadrivalent vaccine targeting HPV 6, 11, 16, and 18. In France, HPV vaccination is recommended in 11-14 year-old
girls with a catch-up for girls aged 15-19. The objective of this study was to assess the potential impact of an HPV
6/11/16/18/31/33/45/52/58 nonavalent vaccine on anogenital and oropharyngeal HPV-related diseases in France.
Methods: HPV genotype distributions from 6 multicentric retrospective studies (EDiTH I to VI) were analyzed including
516 cases of invasive cervical cancers (ICC), 493 high-grade cervical neoplasias (CIN2/3), 397 low-grade squamous
intraepithelial lesions (LSIL), 423 GW, 366 anal cancer and 314 oropharyngeal carcinomas. Low and high estimates of
HPV vaccine impact were calculated as follows: low estimate: prevalence of HPV 6/11/16/18/31/33/45/52/58 genotypes
alone or in association but excluding presence of another HPV type; high estimate: prevalence of HPV 6/11/16/18/31/
33/45/52/58 genotypes alone or in association, possibly in presence of another HPV type.
Results: Estimates of potential impact varied from 85% (low estimate) to 92% (high estimate) for ICC, 77% to 90% for
CIN2/3, 26% to 56% for LSIL, 69% to 90% for GW, 81% to 93% for anal cancer, and 41% to 44% for oropharyngeal
carcinomas. Compared to the quadrivalent vaccine, the proportion of additional cases potentially prevented by
the nonavalent vaccine was 9.9%-15.3% for ICC, 24.7%-33.3% for CIN2/3, 12.3%-22.7% for LSIL, 2.1%-5.4% for GW,
8.5%-10.4% for anal cancer, and 0.0%-1.6% for oropharyngeal carcinoma.
Conclusions: The nonavalent HPV vaccine showed significant increased potential impact compared to the HPV
6/11/16/18 quadrivalent vaccine for ICC, CIN2/3 and LSIL. Considering a 100% vaccine efficacy and high vaccine
coverage, about 90% of ICC, CIN2/3, GW or anal cancer cases could be prevented by a nonavalent HPV vaccine in
France.
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Human Papillomavirus (HPV) infection is known to be
associated with a number of conditions including cer-
vical, vaginal, vulvar, penile, anal neoplasias and cancers,
oropharynx cancers and genitals warts (GW) [1-5]. Two
prophylactic vaccines using L1 virus-like particles (VLP)
are available and widely marketed internationally. These
vaccines were primarily developed with the aim of reducing* Correspondence: acjacquard@spmsd.com
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bivalent vaccine designed to prevent high-risk HPV type 16
and 18 infection. The second one (Gardasil®), is a quadriva-
lent vaccine targeting HPV 6, 11, 16, and 18 [6], HPV low-
risk types 6 and 11 being associated with 90% of GW [7,8].
In France, HPV vaccination is recommended in 11-14 year-
old girls with a catch-up for girls aged 15-19 [9].
Worldwide studies in invasive cervical cancer (ICC)
cases reported that the most commonly encountered HPV
types after HPV 16 and 18 were HPV 31, 33, 35, 45, 52,
and 58 [10,11]. Merck has been developing a nonavalenttral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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(HPV 31/33/45/52/58) to the HPV types 6/11/16/18 con-
tained in the quadrivalent vaccine [12]. Serrano et al. esti-
mated that the addition of HPV 31/33/45/52/58 to HPV
types included in current vaccines could prevent almost
90% of ICC cases worldwide [13].
The French EDiTH studies (Etude de la Distribution des
Types d’HPV) reported the HPV genotype distribution in
invasive cervical cancer (EDiTH I) [14], high-grade cer-
vical neoplasias (CIN2/3) (EDiTH II) [15], low-grade squa-
mous intraepithelial lesions (LSIL) (EDiTH III) [16],
external acuminata condylomata (genital warts) (EDiTH
IV) [17], anal cancer (EDiTH V) [18] and oropharyngeal
cancer (EDiTH VI) [19]. In these studies, the estimated
potential impact of a 6/11/16/18 quadrivalent vaccine var-
ied from 14-33% in LSIL to about 70-83% in cervical or
anal cancers.
These studies have shown that a proportion of HPV-
related lesions were not targeted by currently available
vaccines. The objective of the present study was thus to
assess the potential impact in France of a 6/11/16/18/31/
33/45/52/58 nonavalent HPV vaccine on anogenital and
oropharyngeal HPV-related diseases, and to compare this
impact with the 6/11/16/18 quadrivalent vaccine.
Methods
Studies
We reanalyzed data from 6 multicenter retrospective stud-
ies (EDiTH I to EDiTH VI) published elsewhere [14-19].
For each study, details regarding patients’ data, histological
specimens’ inclusion/exclusion criteria, DNA isolation,
HPV genotyping and ethical considerations can be found
in the respective publications.
Statistical analysis
Histological specimens of 516 invasive cervical cancers
(HPV prevalence, 97.1%), 493 high grade cervical neopla-
sias (HPV prevalence, 98.2%), 397 low-grade squamous
intraepithelial lesions (HPV prevalence, 98.2%), 423 exter-
nal acuminata condylomata (HPV prevalence, 98.8%), 366
anal cancer (HPV prevalence, 96.7%) and 314 oropharyn-
geal carcinomas (HPV prevalence, 46.5%) were included
in the analysis.
For each condition, HPV genotype distributions were
used to assess the potential impact of the quadrivalent
and the nonavalent vaccines in France. A low and a high
estimate of the vaccine impact were calculated as fol-
lows. For the quadrivalent vaccine, low estimate was the
prevalence of HPV 6/11/16/18 genotypes alone or in as-
sociation but excluding presence of another HPV type;
high estimate was the prevalence of HPV 6/11/16/18 ge-
notypes alone or in association possibly in presence of
another HPV type. For the nonavalent vaccine, low esti-
mate was the prevalence of HPV 6/11/16/18/31/33/45/52/58 genotypes alone or in association but excluding
presence of another HPV type; high estimate was the
prevalence of HPV 6/11/16/18/31/33/45/52/58 geno-
types alone or in association possibly in presence of an-
other HPV type. Additional file 1: Table S1 presents
genotypes and combination of genotypes used to define
the low and high estimates for the quadrivalent and non-
avalent vaccines. Estimates are presented with their 95%
confidence intervals calculated based on the cumulative
binomial distribution.
The absolute additional potential impact of the nona-
valent vaccine, i.e. the proportion of additional cases po-
tentially prevented by the nonavalent vaccine compared




with n being the number of cancer cases potentially pre-
vented and N the total number of cancer cases.
The relative additional potential impact of the nonava-





with n representing the number of potentially prevented
cancer cases.
Results
HPV genotypes in the six EDiTH studies are described
in details in Table 1. Single infections by HPV 6/11/16/
18/31/33/45/52/58 were found in 362 (70.2%), 299
(60.6%), 84 (21.2%), 251 (59.3%), 257 (70.2%) and 130
(41.4%) of invasive cervical cancers, high-grade cervical
neoplasias, low-grade squamous intraepithelial lesions,
external acuminata condylomata, anal cancer and oropha-
ryngeal carcinomas, respectively. Corresponding multiple
infections by HPV 6/11/16/18/31/33/45/52/58, excluding
any other HPV genotype, were found in 74 (14.3%), 79
(16.0%), 19 (4.8%), 39 (9.2%), 39 (10.7%) and 0 (0,0%), and
corresponding multiple infections by HPV 6/11/16/18/31/
33/45/52/58, with or without another HPV genotype, in
113 (21,9%), 142 (28,8%), 139 (35,0%), 131 (31,0%), 84
(23,0%) and 8 (2,5%).
The potential impact of the quadrivalent and nonava-
lent HPV vaccines assessed by low and high estimates is
presented in Figure 1. The nonavalent HPV vaccine
showed increased impact compared to the quadrivalent
vaccine for invasive cervical cancers, high-grade cervical
neoplasias and low-grade squamous intraepithelial le-
sions. The number of genotypes targeted by the nona-
valent vaccine varied between 84.5% (low estimate,
95%CI 81.0 to 87.8) and 92.1% (high estimate, 95%CI
89.5 to 94.3) for invasive cervical cancers, between











n n n n n n
HPV (+) 501 (97.1) 484 (98.2) 390 (98.2) 418 (98.8) 354 (96.7) 146 (46.5)
HPV (-) 15 (2.9) 9 (1.8) 7 (1.8) 5 (1.2) 12 (3.3) 168 (53.5)
Total 516 (100) 493 (100) 397 (100) 423 (100) 366 (100) 314 (100)
Total single infections 386 (74.8) 333 (67.5) 192 (48.4) 281 (66.4) 265 (72.4) 138 (43.9)
Total single infections 6/11/16/18 316 (61.2) 203 (41.2) 50 (12.6) 248 (58.6) 234 (63.9) 130 (41.4)
Single infections 6 1 (0.2) 0 (0.0) 11 (2.8) 195 (46.1) 13 (3.6) 0 (0.0)
Single infections 11 1 (0.2) 1 (0.2) 0 (0.0) 42 (9.9) 4 (1.1) 0 (0.0)
Single infections 16 275 (53.3) 199 (40.4) 31 (7.8) 11 (2.6) 216 (59.0) 130 (41.4)
Single infections 18 39 (7.6) 3 (0.6) 8 (2.0) 0 (0.0) 1 (0.3) 0 (0.0)
Total single infections 31/33/45/52/58 46 (8.9) 96 (19.5) 34 (8.6) 3 (0.7) 23 (6.3) 0 (0.0)
Single infections 31 17 (3.3) 41 (8.3) 8 (2.0) 1 (0.2) 4 (1.1) 0 (0.0)
Single infections 33 11 (2.1) 27 (5.5) 1 (0.3) 0 (0.0) 11 (3.0) 0 (0.0)
Single infections 45 9 (1.7) 0 (0.0) 6 (1.5) 0 (0.0) 0 (0.0) 0 (0.0)
Single infections 52 6 (1.2) 13 (2.6) 8 (2.0) 1 (0.2) 5 (1.4) 0 (0.0)
Single infections 58 3 (0.6) 15 (3.0) 11 (2.8) 1 (0.2) 3 (0.8) 0 (0.0)
Total single infections 6/11/16/18/31/33/45/52/58 362 (70.2) 299 (60.6) 84 (21.2) 251 (59.3) 257 (70.2) 130 (41.4)
Single infections others 24 (4.7) 34 (6.9) 108 (27.2) 30 (7.1) 8 (2.2) 8 (2.5)
Total multiple infections 115 (22.3) 151 (30.6) 198 (49.9) 137 (32.4) 89 (24.3) 8 (2.5)
Multiple infections 6/11/16/18 excluding any other
HPV genotypes
41 (7.9) 11 (2.2) 4 (1.0) 19 (4.5) 24 (6.6) 0 (0.0)
Multiple infections 6/11/16/18 with or without
another HPV genotype
108 (20.9) 116 (23.5) 83 (20.9) 125 (29.6) 76 (20.8) 3 (1.0)
Multiple infections 6/11/16/18/31/33/45/52/58
excluding any other HPV genotypes
74 (14.3) 79 (16.0) 19 (4.8) 39 (9.2) 39 (10.7) 0 (0.0)
Multiple infections 6/11/16/18/31/33/45/52/58 with
or without another HPV genotype
113 (21.9) 142 (28.8) 139 (35.0) 131 (31.0) 84 (23.0) 8 (2.5)
Multiple infections other HPV excluding
6/11/16/18/31/33/45/52/58














Figure 1 Potential impact of quadrivalent and nonavalent HPV vaccines on invasive cervical cancers, high-grade cervical neoplasias, low-grade
squamous intraepithelial lesions, external acuminata condylomata, anal cancers, and oropharyngeal carcinomas in France.
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92.3) for high-grade cervical neoplasias, and between
25.9% (95%CI 17.5 to 35.0) and 56.2% (95%CI 49.8 to
62.8) for low-grade squamous intraepithelial lesions.
The absolute additional impact of the nonavalent
vaccine (i.e the number of additional cases that could
be prevented by the nonavalent vaccine) as well as the
relative additional impact (i.e compared to the quadri-
valent vaccine) are presented in Table 2. Again, limited
impact was found for the nonavalent vaccine com-
pared to the quadrivalent one for external acuminata
condylomata, anal cancer and oropharyngeal carcin-
omas. The absolute additional impact of the nonava-
lent vaccine lied between 9.9% and 15.3% for invasive
cervical cancers, between 24.7% and 33.3% for high-
grade cervical neoplasias, and between 12.3% and
22.7% for low-grade squamous intraepithelial lesions.
The benefit of the nonavalent vaccine compared to
the quadrivalent vaccine ranged between 12.0% and
22.1% for invasive cervical cancers, between 38.2%
and 76.6% for high grade cervical neoplasias, and
between 67.7% and 90.7% for low-grade squamous
intraepithelial lesions.Discussion
Based on large number of cases, the national multicentre
EDiTH studies previously reported the HPV genotype
distribution for different cervical, anal, or oropharyngeal
diseases in France [14-20]. Assuming a 100% vaccine ef-
ficacy and vaccination coverage, the EDiTH results sug-
gested that a 6/11/16/18 quadrivalent HPV vaccine
could prevent between 70% and 83% of ICC and anal
cancer cases.
The attribution of cases to HPV types is often compli-
cated by the existence of multiple infections character-
ized by the presence of several HPV types in the same
tumor. Therefore, the potential benefit of an HPV vac-
cine is difficult to assess especially when HPV types not
targeted by the vaccine are present. In all EDiTH studies
and in the present study as well, we thus calculated a
low and a high estimate of the vaccine impact based on
presence of single or multiple infections. It is possible
that the high estimate gives an overestimation of the po-
tential impact of the vaccine since one assumes that
HPV types targeted by the vaccine are causally related to
the lesion in which they are found even in the presence
of another HPV type. It is thus reasonable to believe that
Table 2 Overall proportion (low and high estimates) of cases targeted by a quadrivalent or a nonavalent HPV vaccine
Low estimate High estimate
Invasive cervical cancers (EDITH I) Quadrivalent 69.2 [64.4-73.9] 82.2 [78.5-85.8]
Nonavalent 84.5 [81.0-87.8] 92.1 [89.5-94.3]
Absolute additional Impact*
(% of additional prevented cases)
15.3% (p < 0.001) 9.9% (p < 0.001)
Relative additional Impact** 22.1% 12.0%
High-grade cervical neoplasias (EDITH II) Quadrivalent 43.4 [36.9-50.0] 64.7 [59.6-69.9]
Nonavalent 76.7 [72.2-81.0] 89.5 [86.4-92.3]
Absolute additional Impact
(% of additional prevented cases)
33.3% (p < 0.001) 24.7% (p < 0.001)
Relative additional Impact 76.6% 38.2%
Low-grade squamous intraepithelial lesions (EDITH III) Quadrivalent 13.6 [5.6-24.1] 33.5 [25.6-41.4]
Nonavalent 25.9 [17.5-35.0] 56.2 [49.8-62.8]
Absolute additional Impact
(% of additional prevented cases)
12.3% (p < 0.001) 22.7% (p < 0.001)
Relative additional Impact 90.7% 67.7%
External acuminata condylomata (EDITH IV) Quadrivalent 63.1 [57.3-68.9] 88.2 [84.7-91.4]
Nonavalent 68.6 [63.1-73.8] 90.3 [87.2-93.2]
Absolute additional Impact
(% of additional prevented cases)
5.4% (p = 0.095) 2.1% (p = 0.318)
Relative additional Impact 8.6% 2.4%
Anal cancers (EDITH V) Quadrivalent 70.5 [64.7-76.0] 84.7 [80.6-88.7]
Nonavalent 80.9 [76.4-85.1] 93.2 [90.3-95.6]
Absolute additional Impact
(% of additional prevented cases)
10.4% (p = 0.001) 8.5% (p < 0.001)
Relative additional Impact 14.7% 10.0%
Oropharyngeal carcinomas (EDITH VI) Quadrivalent 41.4 [33.1-50.0] 42.4 [33.8-51.1]
Nonavalent 41.4 [33.1-50.0] 43.9 [35.5-52.2]
Absolute additional Impact
(% of additional prevented cases)
0.0% (NC) 1.6% (p = 0.687)
Relative additional Impact 0.0% 3.8%
*Absolute additional potential impact of the nonavalent vaccine.
**Relative additional potential impact of the nonavalent vaccine.
NC, not calculated.
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low and the high estimates.
If low estimate calculations are considered, the present
study indicates that the absolute additional impact of a
nonavalent vaccine is highest for CIN2/3 with a 33% in-
crease in the proportion of cases targeted by the nonava-
lent vaccine. This additional benefit is intermediate for
ICC (15% increase), LSIL (12%) and anal cancer (10%)
whereas almost no additional benefit is observed for
genital warts (5%) and oropharyngeal carcinomas (0%).
The EDiTH II study showed that between 43% and 65%
of CIN2/3 cases were associated with HPV 6/11/16/18
(low and high estimates) [15] whereas the present study
indicates that a nonavalent vaccine could target 77% and
up to 90% of all CIN2/3 cases. This benefit on the pre-
vention of CIN2/3 cases could have a real public healthimpact by reducing the costs related to the management
of these lesions. It is indeed estimated that 25,000 to
30,000 conizations are performed in France annually
[21]. The benefit on ICC would also be substantial with
up to 92% of ICC cases that could be targeted by a non-
avalent vaccine. Even if the proportion of LSIL cases at-
tributed to HPV 6/11/16/18 was rather low (14-34%),
the proportion of cases associated with HPV types tar-
geted by the nonavalent vaccine is increased by almost
90% (14% vs 26% considering the low estimates). How-
ever, for genital warts, only about 5% of cases are attrib-
uted to the additional HPV types found in the
nonavalent vaccine (HPV 31/33/45/52/58) resulting in a
low efficacy benefit. Similarly, no oropharyngeal carcin-
oma case was associated with these additional HPV
types suggesting no additional benefit of a nonavalent
Riethmuller et al. BMC Public Health  (2015) 15:453 Page 6 of 7vaccine in this group. This limited additional benefit on
oropharyngeal carcinoma and genital warts is mainly ex-
plained by the fact that these conditions are almost ex-
clusively associated with HPV types targeted by the
bivalent or quadrivalent vaccines. Anal cancers are
known to be mainly associated with HPV 16. A possible
explanation for the observed additional benefit of the
nonavalent vaccine (15%) is that we included some HIV
positive patients (14%) with higher risk of multiple infec-
tion (50% vs 20% in HIV negative patients).
It should be noticed that a strong epidemiological im-
pact characterized by significant reductions in HPV-
related precancerous lesions and cancers may be achieved
only if vaccination coverage reaches more than 80% [22].
However, by the end of 2013, the vaccination coverage
with 3 doses reached only 20% of 16 year-old women in
France [23]. By raising public awareness of the importance
of HPV vaccination, general practitioners and gynecolo-
gists have to play an important role for increasing vaccin-
ation coverage.
A possible limitation of the present study is that HPV
positivity in the EDiTH studies was based on HPV DNA
detection only which could have resulted in a slight
overestimation of the proportion of cancers potentially
attributed to HPV. This is particularly true for oropha-
ryngeal carcinomas for which HPV RNA detection
would be a more accurate marker for those related to
HPV infection. Moreover, other risk factors such as
smoking or alcohol abuse are possibly involved. We cal-
culated low and high estimates with the aim of taking
into account the lack of knowledge regarding the causal
relationship between each lesion and multiple HPV in-
fection types. Low estimates suppose that the vaccine
only prevents cases with genotypes targeted by the vac-
cine, while high estimates rather suppose that the vac-
cine prevents all cases where at least one genotype
targeted by the vaccine is present, even in the presence
of another genotype. This assumes that the other geno-
type is not involved in the occurrence of the lesion. Of
course, true effects are in-between and it should be
noted that alternative methods based on proportional
(i.e., weighted) or hierarchical attributions of genotypes
to disease categories have been proposed, providing
intermediate estimates [10,24,25]. We nevertheless pre-
ferred to report estimates intervals rather that single
estimates.
However, our results are in accordance with previous
results reporting that a nonavalent vaccine would in-
crease the protection from 70% to almost 90% of the
infections responsible for ICC [13]. Moreover, a model-
based analysis showed that at the population level, the
switch from a bivalent or a quadrivalent to a nonava-
lent vaccine would further reduce the occurrence of
precancerous lesions and cervical cancer [26].In France, both the bivalent and the quadrivalent vac-
cines are available with a predominant use of the
quadrivalent [27]. Gardasil is currently indicated for
the prevention of premalignant genital lesions (cervical,
vulvar and vaginal), premalignant anal lesions, cervical
cancers, anal cancers, and genital warts (condyloma acu-
minata) causally related to specific HPV types [28]. It
should thus be borne in mind that the potential vaccine
impact we assessed is hypothetical and concerns some
outcomes (e.g. oropharyngeal carcinoma) for which no
specific indication exists yet.
Pap smear screening is and will remain a very efficient
tool for the prevention of ICC. Even if screening of eld-
erly women should still be highly recommended, HPV
vaccination could reduce and hinder the spread of the
virus and prevent HPV-related diseases and cancers for
which no screening strategies are available.
Conclusion
The nonavalent HPV vaccine showed significant in-
creased potential impact compared to the HPV 6/11/16/
18 quadrivalent vaccine for ICC, CIN2/3 and LSIL. Non-
avalent vaccination could thus be a cost-effective alter-
native [29] with almost 90% of ICC, CIN2/3, genital
warts and anal cancer cases being potentially prevented.
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